AWAleksandra Wądołowska

Aleksandra Wądołowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Wądołowska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SLEEP QUALITY (PSQI) AND SUMMATIVE EXAM PERFORMANCE IN MEDICAL STUDENTS

    by Aleksandra Wądołowska, Blanka Serafin-Juszczak, Maria Wydra, Zuzanna Mogilany, Jan Wojdal, Karolina Kusek, Barbara Przybył, Katarzyna Ciepłucha, Michał Wilk, Daniel Narożniak

    Purpose of the research: This study aimed to review the relationship between sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), and academic performance among medical students, highlighting neurocognitive consequences and effective interventions. Materials and methods: The review of research literature was conducted through databases such as PubMed, Google Scholar, and Scopus, including studies from 2007 to 2025. Results: Multiple studies show that poor sleep quality (PSQI >5) is highly prevalent among medical students and often correlates with reduced GPA, impaired memory, and diminished executive function. Acute sleep deprivation before exams significantly worsens performance. However, inconsistent methodologies, self-reported data, and cross-sectional designs limit causal interpretation. Despite this, evidence supports implementing sleep hygiene education, CBT-I, mindfulness training, and institutional changes to promote better sleep and academic outcomes. Conclusions: A multifaceted approach is needed to improve medical students’ sleep. Combining behavioural interventions and structural academic reforms may reduce stress, enhance cognitive performance, and support long-term academic success. Further longitudinal research using objective measures is recommended to strengthen these findings.

  • Open Access

    MENOPAUSAL HORMONE THERAPHY – APPLICATION, RISKS AND BENEFITS IN CLINICAL PRACTICE

    by Aleksandra Wądołowska, Blanka Serafin-Juszczak, Maria Wydra, Zuzanna Mogilany, Jan Wojdal, Karolina Kusek, Barbara Przybył, Katarzyna Ciepłucha, Michał Wilk, Daniel Narożniak

    Aim of the study: The aim of this review is to explore current evidence regarding physiological rationale, indications, contraindications and systemic use of MHT in clinical practice. Materials and methods: Literature reviewed was conducted in medical databases such as PubMed, UpToDate and relevant subject literature published within last 30 years. Results: Evidence indicates that early initiation (< 10 years after the onset of menopause) of combined estrogen-progestogen therapy significantly diminishes coronary events and prevents rapid bone loss, whereas later commencement increases ischaemic stroke and venous thrombo-embolism risk. Unopposed systemic oestrogen elevates endometrial-carcinoma incidence, and long-term systemic regimens may moderately increase breast-cancer risk. On the contrary, topical vaginal oestrogens reverse urogenital atrophy and lower recurrent urinary-tract infection rates with minimal systemic exposure. Conclusion: MHT consistently alleviates vasomotor symptoms and improves quality of life, but does not constitute first-line therapy for established osteoporosis or primary cardiovascular prevention The therapeutic value of MHT is contingent upon timing, formulation, route and patient-specific comorbidities. When used for the shortest necessary duration and accompanied by careful surveillance, MHT offers substantial symptomatic benefit with acceptable safety in appropriately selected women.

  • Open Access

    Cardiotoxicity in cancer immunotherapy: from pathogenesis to prevention ? narrative review

    by Mateusz Mierniczek, Daniel Narożniak, Maria Mierniczek, Wiktoria Mika, Anna Rodzeń, Jan Wojdal, Katarzyna Ciepłucha, Aleksandra Wądołowska, Barbara Przybył

    Cancer immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, improve survival but carry a risk of severe cardiotoxicity. Myocarditis is the most dangerous complication with high mortality, and its mechanism involves T-cell auto-aggression or cytokine storms. Risk management requires vigilance, monitoring of cardiac biomarkers, and imaging studies. Prompt treatment with high-dose glucocorticosteroids is crucial. Collaboration within cardio-oncology teams is fundamental for safety, and further research must focus on precise risk stratification to protect patients while maintaining therapeutic efficacy.